Document is current
Any future updates will be listed below
-
Authors
Jiang, Longda https://orcid.org/0000-0003-4964-6497
Dalgarno, Carol
Papalexi, Efthymia
Mascio, Isabella
Wessels, Hans-Hermann https://orcid.org/0000-0001-5551-404X
Yun, Huiyoung
Iremadze, Nika https://orcid.org/0000-0002-4977-204X
Lithwick-Yanai, Gila
Lipson, Doron
Satija, Rahul https://orcid.org/0000-0001-9448-8833
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1HG011014-02)
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (1OT2OD033760-01)
Chan Zuckerberg Initiative
- License Information
-
More Information
Article History
Received: 21 February 2024
Accepted: 21 January 2025
First Online: 26 February 2025
Competing interests
: In the past 3 years, R.S. has received compensation from Bristol Myers Squibb, ImmunAI, Resolve Biosciences, Nanostring, 10x Genomics, Parse Biosciences and Neptune Bio. R.S. and H.-H.W. are co-founders and equity holders of Neptune Bio. H.-H.W. has been an employee at Neptune Bio since August 2023. N.I., G.L.-Y. and D.L. are employees and shareholders of Ultima Genomics. E.P. has been an employee at Parse Biosciences since December 2021 and owns stock in the company. The other authors declare no competing interests.
